Bruised by the titanic failure of its Alzheimer’s drug aducanumab and ahead of gene-therapy competition for its flagship SMA treatment Spinraza, Biogen is fortifying its board with three new appointments to placate its increasingly disenchanted shareholder base that has seen the US drugmaker cultivate its pipeline around the now abandoned aducanumab.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,